Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines.
Dizdar
Omer
O
Dede
Didem S
DS
Bulut
Nilufer
N
Altundag
Kadri
K
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D045744:Cell Line, Tumor; D000069439:Dasatinib; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D066246:ErbB Receptors / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism*; D011743:Pyrimidines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D066246:ErbB Receptors; D019009:Proto-Oncogene Proteins c-kit; D000069439:Dasatinib